{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T21:22:06Z","timestamp":1750368126749},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":4896,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[1995,2]]},"abstract":"<jats:p><jats:bold>Abstract<\/jats:bold> Eradication of <jats:italic>Helicobacter pylori<\/jats:italic> infection is known to reduce the incidence of duodenal ulcer recurrence. The most commonly used regimen for <jats:italic>H. pylori<\/jats:italic> infection is triple antimicrobial therapy for 1\u20102 weeks. This treatment is associated with frequent side effects and hence unsatisfactory compliance. As <jats:italic>in vitro<\/jats:italic> data showed that <jats:italic>H. pylori<\/jats:italic> is sensitive to imipenem, the pharmacokinetics of this drug in the gastric milieu, and the clinical efficacy of imipenem with omeprazole in eradicating <jats:italic>H. pylori<\/jats:italic> infection were studied. Imipenem\/cilastatin levels in serum, gastric secretion and gastric mucosa were assayed in four patients after intravenous injection of a bolus dose of 500 mg. The serum and gastric secretion levels of imipenem achieved were more than 10 times the minimum inhibitory concentration of the drug for <jats:italic>H. pylori.<\/jats:italic> Gastric mucosal levels of imipenem vary considerably with time, which probably indicates rapid elimination of the drug into the gastric lumen. In the second part of this study, imipenem\/cilastatin was given intravenously for the first 2 days after diagnosis of <jats:italic>H. pylori<\/jats:italic> infection in patients with endoscopically confirmed duodenal ulcers. The patients were also treated with 4 weeks of omeprazole. Clearance of <jats:italic>H. pylori<\/jats:italic> was initially achieved at the end of 2 days in 20 out of 22 (91%) patients. However, when the biopsies were repeated at 8 weeks, recurrence of <jats:italic>H. pylori<\/jats:italic> infection was evident in 19 cases (86.3%) indicating a failure of eradication. It was concluded that imipenem\/cilastatin in combination with omeprazole failed to eradicate <jats:italic>H. pylori<\/jats:italic> infection.<\/jats:p>","DOI":"10.1111\/j.1440-1746.1995.tb01050.x","type":"journal-article","created":{"date-parts":[[2008,3,10]],"date-time":"2008-03-10T23:44:38Z","timestamp":1205192678000},"page":"66-69","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Mucosal pharmacokinetics and pilot study of short course of parenteral imipenem in the eradication of <i>Helicobacter pylori<\/i>"],"prefix":"10.1111","volume":"10","author":[{"given":"JOSEPH J. Y.","family":"SUNG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. C. SYDNEY","family":"CHUNG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHORLAND W.","family":"HOSKING","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RAPHAEL C. Y.","family":"CHAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"THOMAS K. W.","family":"LING","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MAN\u2010YEE","family":"YUNG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AUGUSTINE F. B.","family":"CHENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ARTHUR K. C.","family":"LI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90929-4"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91301-P"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92111-E"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)90095-G"},{"key":"e_1_2_1_6_2","first-page":"160","volume-title":"Helicobacter pylori in Peptic Ulceration and Gastritis","author":"Marshall B. J.","year":"1991"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91043-A"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.41.2.207"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01962617"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/22.5.729"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/18.Supplement_E.79","article-title":"An overview of the pharmacology of imipenem\/cilastatin","volume":"18","author":"Drusano G. L.","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/27.2.225"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.23.2.300"},{"key":"e_1_2_1_14_2","first-page":"36","article-title":"Helicobacter pylori: Causal agent in peptic ulcer disease","volume":"5","author":"Tytgat G. N. J.","year":"1990","journal-title":"J. Gastroenterol. Hepatol."},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.5.789"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.293.6548.645"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)90527-7"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.2.256"},{"key":"e_1_2_1_19_2","first-page":"70","article-title":"Pharmacokinetic, bacteriological and clinical aspect on the use of doxycycline in patients with active duodenal ulcer associated with Campylobacter pylori","volume":"53","author":"Unge P.","year":"1988","journal-title":"Scan. J. Infect. Dis."},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90606-3"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528909091311"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104043241406"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01537225"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.1995.tb01050.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.1995.tb01050.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T21:16:15Z","timestamp":1698354975000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.1995.tb01050.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1995,2]]}},"alternative-id":["10.1111\/j.1440-1746.1995.tb01050.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.1995.tb01050.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,2]]},"assertion":[{"value":"2008-06-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}